Association between benzodiazepine use and exacerbations and mortality in patients with asthma: A matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 8, 2015, Pages 793-802

  Nakafero, Georgina ^a   Sanders, Robert D ^b   Nguyen Van Tam, Jonathan S ^a   Myles, Puja R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Asthma exacerbation; Benzodiazepines; Mortality; Pharmacoepidemiology; Zopiclone

Indexed keywords

BENZODIAZEPINE; DIAZEPAM; LORAZEPAM; TEMAZEPAM; ZOPICLONE; ANXIOLYTIC AGENT; AZABICYCLO DERIVATIVE; BENZODIAZEPINE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED KINGDOM; YOUNG ADULT; ADOLESCENT; COMORBIDITY; DISEASE COURSE; EPIDEMIOLOGY; FACTUAL DATABASE; GREAT BRITAIN; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ASTHMA; AZABICYCLO COMPOUNDS; BENZODIAZEPINES; CASE-CONTROL STUDIES; CAUSE OF DEATH; COMORBIDITY; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HUMANS; HYPNOTICS AND SEDATIVES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PIPERAZINES; POLYPHARMACY; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84938949726     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3799     Document Type: Article

References (40)

1. The International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. Paris, France, 2011.
2. CDC. FastStats: asthma 2013. (n/d) Available at: http://www.cdc.gov/nchs/fastats/asthma.htm [06 June 2014].
3. Royal College of Physicians. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. RCP: London, 2014.
4. BNF., editor. British National Formulary 63. London: BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012.
5. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific [gamma]-aminobutyric acidA receptor subtypes. Nature 1999; 401(6755): 796-800.
6. Kil N, Zhu JF, VanWagnen C, Abdulhamid I. The effects of midazolam on pediatric patients with asthma. Pediatr Dent 2003; 25(2): 137-142.
7. Amarasuriya UK, Myles PR, Sanders RD. Long-term benzodiazepine use and mortality: are we doing the right studies? Curr Drug Saf 2012; 7(5): 367-371.
8. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. European Respiratory Journal 2014; 44(2): 332-40.
9. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014; 348.
10. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2(1). e000850. DOI: 10.1136/bmjopen-2012-000850.
11. Laschi A, Descotes J, Tachon P, Evreux JC. Adverse influence of diazepam upon resistance to Klebsiella pneumoniae infection in mice. Toxicol Lett 1983; 16(3-4): 281-284.
12. Galdiero F, Bentivoglio C, Nuzzo I, et al. Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci n/d; 57(26): 2413-2423.
13. Sanders RD, Godlee A, Goulding J, et al. Benzodiazepine augmented gamma-aminobutyric acid signaling increases mortality from pneumonia in mice. Crit Care Med 2013; 41(7): 1627-36. DOI: 101097/CCM0b013e31827c0c8d.
14. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013; 68(2): 163-70.
15. Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: Eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med 2009; 5(4): 377-383.
16. Pandharipande P, Sanders R, Girard T, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care 2010; 14(2): R38.
17. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. European Respiratory Journal 1999; 13(2): 349-355.
18. Almirall J, Serra-Prat M, Baron F, Palomera E, Bolíbar I. The use of benzodiazepines could be a protective factor for community-acquired pneumonia (CAP) in ≤60-year-old subjects. Thorax 2013; 68(10): 964-5.
19. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc 2011; 59(10): 1899-1907.
20. Iqbal U, Syed-Abdul S, Nguyen PA, Jian W-S, Li Y-C. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013; 68(6): 591-592.
21. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. European Respiratory Journal 2008; 31(6): 1274-1284.
22. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology & Drug Safety n/d 2009; 18(2): 93-103.
23. Xiang Y-Y, Wang S, Liu M, et al. A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nat Med 2007; 13(7): 862-867.
24. Sanders RD, Hussell T, Maze M. Sedation and immunomodulation. Anesthesiol Clin 2011; 29(4): 687-706.
25. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69(1): 4-14.
26. Dupont WD. Power calculations for matched case-control studies. Biometrics 1988; 44(4): 1157-1168.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-383.
28. Niggebrugge A, Haynes R, Jones A, Lovett A, Harvey I. The index of multiple deprivation 2000 access domain: a useful indicator for public health? Soc Sci Med 2005; 60(12): 2743-2753.
29. World Health Organisation (WHO). BMI classification. 2013. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html [27 July 2013].
30. Porta M (ed.). A Dictionary of Epidemiology (5th edn), Oxford University press; New York, 2008.
31. Newson RB. Scenario comparisons: how much good can we do? 2012. Available at: http://www.imperial.ac.uk/nhli/r.newson/usergp/uk2012/newson_ohp1.pdf.
32. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993; 49(3): 865-872.
33. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44(2): 151-347.
34. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med 1998; 13(4): 243-250.
35. Doran T, Kontopantelis E, Reeves D, Sutton M, Ryan AM. Setting performance targets in pay for performance programmes: what can we learn from QOF? BMJ 2014; 348.
36. Rang H.P., Dale M.M., Ritter J.M., Flower R.J., Henderson G. (eds). Rang and Dale's Pharmacology. (7th edn), Elsevier Inc.; London, 2012.
37. van de Nadort C, Smeets HM, Bont J, Zuithoff NPA, Hak E, Verheij TJM. Prognosis of primary care patients aged 80years and older with lower respiratory tract infection. British Journal of General Practice 2009; 59(561): e110-e115.
38. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004; 363(9422): 1728-1731.
39. Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the self-controlled case series method in drug safety assessment. Expert Opin Drug Saf 2011; 10(3): 337-340.
40. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18(8): 697-703.